To the editor:
Extra-platelet NO and NO ؉ -containing drugs are potent inhibitors of platelet aggregation in humans by cGMP-dependent and cGMP-independent mechanisms
Zhang and colleagues stated in their recent article 1 that it was unknown until their study whether NO donors inhibit platelet function by cGMP-dependent and cGMP-independent mechanisms. Yet we 2,3 and others 4 reported several years ago that S-nitrosocysteine (CSNO) and sodium nitroprusside (SNP; Na 2 [Fe(CN) 6 NO]) inhibit platelet function by cGMP-dependent and cGMP-independent mechanisms. CSNO is a potent NO and NO ϩ donor, 3 a crucially important extra-and intra-cellular S-nitrosating species, 3 and a potent inhibitor (IC 50 , 100nM) of collagen-induced (1 g/mL) aggregation of washed human platelets by different cGMP-independent mechanisms. 3 These mechanisms include inhibition of thromboxane A 2 (TxA 2 ) synthesis by platelet cyclooxygenase-1 (COX-1), blockade of the platelet TxA 2 receptor, and S-nitrosation of cysteine moieties on the platelet surface. 3 SNP is a potent inhibitor of ADP-induced (2M) human platelet aggregation in platelet-rich plasma (PRP) by cGMP-dependent and cGMP-independent mechanisms. 3 These effects were seen at an SNP concentration of only 1M, which is 500 times lower than the SNP concentration used by Zhang et al 1 in mice. At very high concentrations, experimental NO/NO ϩ donors may exert concentration-dependent, diametrically different effects on platelet biochemistry. 5 Our observations indicate that NO/NO ϩ donors can both decrease and increase COX-1 activity ( Figure 1A -B). NO is endogenously produced in various types of cells by constitutive and inducible NO synthase (NOS) isoforms and plays multiple physiologic roles. 6, 7 Blood platelets and red blood cells are considered to express NOS isoforms, but there are doubts about functional erythrocytic 8 and platelet 4,9 NOS. Using a sophisticated gas chromatography-mass spectrometry method, we did not detect any NOS activity in human platelets ( Figure 1C) . Addition of functional recombinant human endothelial NOS to human PRP resulted in NO formation and platelet aggregation inhibition ( Figure 1C ; supplemental Figure 1 , available on the Blood Web site; see the Supplemental Materials link at the top of the online article).
In summary, in human blood platelets and erythrocytes, expression and functionality of NO synthase are in dispute. Extra-platelet NO/NO ϩ species including endothelium-derived NO and NO/NO ϩ -releasing drugs are potent inhibitors of platelet aggregation. They are unlikely to modulate platelet function by influencing platelet L-arginine/NO pathway, but they may modulate platelet COX-1. Effects of NO/NO ϩ donors on platelet function observed experimentally at therapeutically irrelevantly high drug concentrations are rather artifactual and misleading. Extension of observations on platelet function from mice to humans should be treated with caution. in the absence or in the presence of externally added recombinant human endothelial NOS (heNOS, 50 g/mL; ALEXIS) and with all cofactors (5M FAD, 5M FMN, 800M NADPH, 10M tetrahydrobiopterin, 500nM calmodulin, 500M calcium). Incubations were performed at 37°C. Data are shown as mean Ϯ SD. Platelet aggregation was induced by ADP (2M) 3 minutes before starting aggregometric measurements. Reaction was stopped by acetone and [ 15 N]nitrate was measurement by GC-MS. 9 Without heNOS, aggregation was 69%, 68% and 69% and [ 15 N]nitrate enrichment was 7%, 6% and 7%.
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Inhibition of platelet activation by NO involves both cGMP-dependent and -independent mechanisms
We are grateful for the opportunity to reply to the letter from Tsikas et al 1 in regard to our recent publication in Blood. 2 Tsikas et al write that "Zhang and colleagues stated in their recent article that it was unknown until their study whether NO donors inhibit platelet function by cGMP-dependent and cGMP-independent mechanisms." 1page5337 The truth is that we discussed previous findings by citing important literature that NO inhibits platelet function by both cGMP-dependent (references 11, 12, and 16 in Zhang et al 2 ) and -independent mechanisms (references 38, 39, 40, 43, and 45 in Zhang et al 2 ). Although previous reports suggested cGMP-independent mechanisms involved in NO-mediated platelet inhibition, this conclusion was recently disputed by the Friebe group, which reported that inhibition of platelets by NO donors is solely dependent on soluble guanylyl cyclase (sGC) using sGC whole-body knockout mice. [3] [4] [5] Therefore, whether cGMP-independent mechanisms are involved in NO-mediated inhibition of platelets is unclear. I agree that it would be more accurate to say "whether the inhibitory effect of NO on platelet activation involves these sGC/cGMP-independent mechanisms is unclear," instead of saying "whether the inhibitory effect of NO on platelet activation involves these sGC/cGMP-independent mechanisms is not known." Our results show that NO donors at high concentrations inhibited platelet function from sGC conditional knockout mice, which support the conclusion that cGMP-independent mechanisms are involved in NO-mediated platelet inhibition and are also consistent with the previous reports from the authors of this letter.
The data in the letter that showed NO/NO ϩ donors can both decrease and increase COX-1 activity in platelets are not contradictory to our results but support our findings that NO/cGMP plays a biphasic role in platelet activation. [6] [7] [8] Tsikas et al show in their letter that they failed to detect NOS activity in platelets using a sophisticated gas chromatographymass spectrometry method. 1 In our paper we reported that sGC is a required agonist-induced platelet activation and that exogenous NO donors inhibit platelet aggregation and secretion through sGCdependent and -independent mechanisms. 2 Thus our study does not involve whether or not platelets express NOS. However, data shown in the letter are contradictory not only to many previous reports from different groups, 7,9-14 but also to a report from the authors of the letter that L-arginine inhibits platelet aggregation and thromboxane A2 formation through NOS dependent mechanisms (reference 2 in Tsikas et al 1 ).
